Altimmune Inc (ALT.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|69||2018||Chairman of the Board|
|54||2017||President, Chief Executive Officer, Director|
|61||2017||Chief Financial Officer, Executive Vice President - Corporate Development|
|58||2017||Chief Scientific Officer|
|54||2017||Chief Medical Officer|
- BRIEF-Altimmune Announces Financial Results For Year Ended Dec 31
- BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine
- BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program
- BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune
- BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.